Wellington Management Group LLP increased its holdings in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 14.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,178,788 shares of the biotechnology company's stock after acquiring an additional 539,359 shares during the period. Wellington Management Group LLP owned about 7.77% of Prothena worth $69,911,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Prothena by 1,122.9% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company's stock worth $8,812,000 after buying an additional 483,673 shares in the last quarter. Armistice Capital LLC grew its position in Prothena by 42.3% in the second quarter. Armistice Capital LLC now owns 1,560,000 shares of the biotechnology company's stock valued at $32,198,000 after acquiring an additional 464,000 shares during the period. Duncan Williams Asset Management LLC acquired a new position in Prothena during the third quarter worth $816,000. Federated Hermes Inc. bought a new position in shares of Prothena during the second quarter valued at $905,000. Finally, Systematic Financial Management LP grew its holdings in shares of Prothena by 25.8% in the 2nd quarter. Systematic Financial Management LP now owns 193,763 shares of the biotechnology company's stock worth $3,999,000 after purchasing an additional 39,771 shares during the last quarter. Institutional investors own 97.08% of the company's stock.
Prothena Trading Down 2.7 %
Shares of PRTA traded down $0.40 during trading hours on Wednesday, hitting $14.15. 294,116 shares of the stock traded hands, compared to its average volume of 574,743. The business has a fifty day moving average of $16.16 and a 200-day moving average of $19.45. The firm has a market capitalization of $761.41 million, a PE ratio of -5.87 and a beta of 0.09. Prothena Co. plc has a 1-year low of $13.22 and a 1-year high of $41.54.
Prothena (NASDAQ:PRTA - Get Free Report) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.18) by $0.08. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The company had revenue of $0.97 million for the quarter, compared to the consensus estimate of $1.22 million. During the same period in the prior year, the company posted $0.38 EPS. The company's revenue was down 98.9% compared to the same quarter last year. As a group, equities research analysts expect that Prothena Co. plc will post -2.24 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on PRTA. HC Wainwright reissued a "buy" rating and set a $84.00 price target on shares of Prothena in a report on Wednesday, November 13th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Prothena in a report on Monday, September 30th. Oppenheimer reduced their price objective on Prothena from $66.00 to $62.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 14th. StockNews.com lowered Prothena from a "hold" rating to a "sell" rating in a research note on Tuesday, November 19th. Finally, Bank of America cut their price target on Prothena from $33.00 to $31.00 and set a "neutral" rating for the company in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $61.86.
Check Out Our Latest Analysis on PRTA
About Prothena
(
Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Further Reading
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
